Utilization Management Program Components
Updated November 2024
- Provincial Guidelines for RSV Infection Prophylaxis:
- For Provincial guidelines refer to the “Nova Scotia Guidelines for RSV Infection Prophylaxis (2024 – 2025)” document.
- Communication/Education to key stakeholders:
- Each year a letter with a copy of the guidelines, directions to health care providers on how to apply to the program (Nova Scotia request form) are distributed to Nova Scotia pediatricians/Executive Directors/VPs and physicians identified by the neonatal intensive care units and other key stakeholders, is distributed and posted on the IWK website.
- An article will be published in the DoctorsNS magazine reviewing the guidelines each fall. The revised Nova Scotia request form and the full 2024/25 guidelines, utilization management program is available at iwkhealth.ca/nirsevimab/
- Monitoring and Reporting of nirsevimab cost and utilization data:
- IWK Health RSV Prevention Program will continue to monitor nirsevimab utilization data and costs associated with this product and report this information back to key stakeholders.
- Results from monitoring the defined start and end date for the RSV season will be reviewed to decide if modifications are required for the next season.
- The guidelines, utilization management program and national recommendations for the use of nirsevimab will be reviewed by the working group at the end of the 2024-25 RSV season. Any further evidence, including cost-benefit analysis, which becomes available, will also be reviewed to ensure continuing efficient and effective use of nirsevimab and determine if there is a need to adjust the guidelines. IWK Health’s results from monitoring nirsevimab, utilization data and costs associated, for the 2024-25 RSV season will be included as part of the review.